• TREMFYA® (guselkumab) showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 study1,2 • Guselkumab demonstrated more than 2 times greater reduction in MRI-assessed inflammation versus placebo at Week 24 in the sacroiliac joints, which connect the lower spine to the pelvis and are responsible for pain and stiffness1,3 • Guselkumab was evaluated in first-ever PsA study using objective MRI assessments to confirm axial inflammation alongside patient-reported symptoms1,4